Edesa Biotech announced that it has selected JSS Medical Research, Inc. as the clinical research organization for its Phase 2 study of EB06, an anti‑CXCL10 monoclonal antibody designed to treat moderate‑to‑severe non‑segmental vitiligo.
The company has begun outreach to potential clinical sites and investigators, with site activations and patient recruitment slated to start in mid‑2026 after approval of its clinical trial application in Canada. This milestone moves EB06 closer to regulatory submission and potential commercialization, extending Edesa’s dermatology pipeline beyond its Phase 3‑ready EB01 asset.
EB06 targets CXCL10, a chemokine implicated in the autoimmune destruction of melanocytes. The drug could fill a large unmet need, as the only FDA‑approved systemic therapy for vitiligo, Opzelura, carries a black‑box warning and there are few effective alternatives. The vitiligo market is projected to reach roughly $1.1 billion by 2030, underscoring the commercial potential of a safer, targeted biologic.
CEO Par Nijhawan said that discussions with key opinion leaders, including those at the recent vitiligo conference, informed the trial design and plans. “Developing an effective and well‑targeted biologic drug—especially for high body surface areas—would have a significant impact on treating vitiligo,” he noted, highlighting the company’s focus on addressing a disease with limited treatment options.
Edesa is a clinical‑stage company with no current revenue and significant R&D expenses. As of December 12 2025, it held approximately $10.8 million in cash and cash equivalents. The Phase 2 milestone is expected to extend the company’s runway while positioning EB06 for future regulatory and commercial opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.